Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation

Kidney International

Volumn 86, Issue 2, 2014, Pages 358-369

  Li, Szu Yuan ^a   Huang, Po Hsun ^a   Yang, An Hang ^a   Tarng, Der Cherng ^a   Yang, Wu Chang ^a   Lin, Chih Ching ^a   Chen, Jaw Wen ^a   Schmid Schönbein, Geert ^b   Lin, Shing Jong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

diabetes mellitus; diabetic nephropathy; matrix metalloproteinases; podocyte

Indexed keywords

ALBUMIN; GELATINASE B; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYTOKINE; MMP9 PROTEIN, HUMAN; MMP9 PROTEIN, MOUSE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEDIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME RELEASE; EXTRACELLULAR MATRIX; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KIDNEY HYPERTROPHY; MALE; MATRIX METALLOPROTEINASE 9 GENE; MICROALBUMINURIA; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; CELL CULTURE; DEFICIENCY; DIABETIC NEPHROPATHIES; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; URINE;

ALBUMINURIA; ANIMALS; CELL DEDIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; PODOCYTES; UP-REGULATION;

EID: 84905514024     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.67     Document Type: Article

References (60)

1. Reutens AT PL, Atkins R. The epidemiology of diabetic kidney disease. In: Ekoé J-M RM, Williams R, Zimmet P (ed). The Epidemiology of Diabetes Mellitus, 2nd edn. John Wiley & Sons: Chichester, 2008 pp 499-518.
2. International comparisions. United States Renal Data System, 2012.
3. Coca SG, Ismail-Beigi F, Haq N et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Int Med 2012; 172: 761-769.
4. de Boer IH, Sun W, Cleary PA et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-2376.
5. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32(Suppl 2): 64-78.
6. Naduk-Kik J, Hrabec E. The role of matrix metalloproteinases in the pathogenesis of diabetes mellitus and progression of diabetes retinopathy. Postepy Hig Med Dosw (Online) 2008; 62: 442-450.
7. Descamps FJ, Martens E, Kangave D et al. The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp Eye Res 2006; 83: 401-407.
8. Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2011; 20: 47-54.
9. Montaner J, Alvarez-Sabin J, Molina CA et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001; 32: 2762-2767.
10. Asahi M, Wang X, Mori T et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724-7732.
11. Carew RM, Wang B, Kantharidis P. The role of EMT in renal fibrosis. Cell Tissue Res 2012; 347: 103-116.
12. Hills CE, Siamantouras E, Smith SW et al. TGFbeta modulates cell-to-cell communication in early epithelial-to-mesenchymal transition. Diabetologia 2012; 55: 812-824.
13. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-222.
14. Herman-Edelstein M, Thomas MC, Thallas-Bonke V et al. Dedifferentiation of immortalized human podocytes in response to transforming growth factor-beta: a model for diabetic podocytopathy. Diabetes 2011; 60: 1779-1788.
15. Li Y, Kang YS, Dai C et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008; 172: 299-308.
16. Yamaguchi Y, Iwano M, Suzuki D et al. Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 2009; 54: 653-664.
17. Saleem MA, Zavadil J, Bailly M et al. The molecular and functional phenotype of glomerular podocytes reveals key features of contractile smooth muscle cells. Am J Physiol Renal Physiol 2008; 295: F959-F970.
18. Zheng G, Lyons JG, Tan TK et al. Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol 2009; 175: 580-591.
19. Tan TK, Zheng G, Hsu TT et al. Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells. Am J Pathol 2010; 176: 1256-1270.
20. Kang YS, Li Y, Dai C et al. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 2010; 78: 363-373.
21. Li Y, Yang J, Dai C et al. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 2003; 112: 503-516.
22. Makino H, Yamasaki Y, Haramoto T et al. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab Invest 1993; 68: 45-55.
23. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020.
24. Sharma K, Jin Y, Guo J et al. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-530.
25. Bai Y, Wang L, Li Y et al. High ambient glucose levels modulates the production of MMP-9 and alpha5(IV) collagen by cultured podocytes. Cell Physiol Biochem 2006; 17: 57-68.
26. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrinlinked protein kinase. Nature 1996; 379: 91-96.
27. Dai C, Stolz DB, Bastacky SI et al. Essential role of integrin-linked kinase in podocyte biology: Bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol 2006; 17: 2164-2175.
28. Guo L, Sanders PW, Woods A et al. The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. Am J Pathol 2001; 159: 1735-1742.
29. Yan Q, Sui W, Xie S et al. Expression and role of integrin-linked kinase and collagen IV in human renal allografts with interstitial fibrosis and tubular atrophy. Transpl Immunol 2010; 23: 1-5.
30. Kobayashi N, Mominoki K, Wakisaka H et al. Morphogenetic activity of extracellular matrices on cultured podocytes. Laminin accelerates podocyte process formation in vitro. Ital J Anat Embryol 2001; 106: 423-430.
31. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008; 4: 444-452.
32. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
33. Kanwar YS, Wada J, Sun L et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008; 233: 4-11.
34. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 2007; 292: F1665-F1672.
35. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol 2012; 302: F1351-F1361.
36. Cheng S, Pollock AS, Mahimkar R et al. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006; 20: 1898-1900.
37. Tsai JP, Liou JH, Kao WT et al. Increased expression of intranuclear matrix metalloproteinase 9 in atrophic renal tubules is associated with renal fibrosis. PloS One 2012; 7: e48164.
38. Kunugi S, Shimizu A, Kuwahara N et al. Inhibition of matrix metalloproteinases reduces ischemia-reperfusion acute kidney injury. Lab Invest 2011; 91: 170-180.
39. Lee SY, Horbelt M, Mang HE et al. MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injury. Am J Physiol Renal Physiol 2011; 301: F101-F109.
40. Wang X, Zhou Y, Tan R et al. Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2010; 299: F973-F982.
41. Kluger MA, Zahner G, Paust HJ et al. Leukocyte-derived MMP9 is crucial for the recruitment of proinflammatory macrophages in experimental glomerulonephritis. Kidney Int 2013; 83: 865-877.
42. McLennan SV, Kelly DJ, Cox AJ et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002; 45: 268-275.
43. Maric C, Sandberg K, Hinojosa-Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol 2004; 15: 1546-1556.
44. Williams JM, Zhang J, North P et al. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 2011; 300: F983-F998.
45. Kumar Bhatt L, Addepalli V. Minocycline with aspirin: an approach to attenuate diabetic nephropathy in rats. Ren Fail 2011; 33: 72-78.
46. Takamiya Y, Fukami K, Yamagishi SI et al. Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrol Dial Transplant 2012; 28: 55-62.
47. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163-176.
48. Gharagozlian S, Svennevig K, Bangstad HJ et al. Matrix metalloproteinases in subjects with type 1 diabetes. BMC Clin Pathol 2009; 9:7.
49. Garvin P, Nilsson L, Carstensen J et al. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PloS One 2008; 3: e1774.
50. Arnould C, Lelievre-Pegorier M, Ronco P et al. MMP9 limits apoptosis and stimulates branching morphogenesis during kidney development. J Am Soc Nephrol 2009; 20: 2171-2180.
51. Qi Z, Fujita H, Jin J et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005; 54: 2628-2637.
52. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010; 21: 1247-1253.
53. Quaggin SE, Kapus A. Scar wars: mapping the fate of epithelialmesenchymal- myofibroblast transition. Kidney Int 2011; 80: 41-50.
54. Qi Z, Whitt I, Mehta A et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004; 286: F590-F596.
55. Najafian B, Basgen JM, Mauer M. Estimating mean glomerular volume using two arbitrary parallel sections. J Am Soc Nephrol 2002; 13: 2697-2705.
56. Shankland SJ, Pippin JW, Reiser J et al. Podocytes in culture: past, present, and future. Kidney Int 2007; 72: 26-36.
57. Takano Y, Yamauchi K, Hiramatsu N et al. Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin. Am J Physiol Renal Physiol 2007; 292: F1573-F1582.
58. Oshima T, Laroux FS, Coe LL et al. Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc Res 2001; 61: 130-143.
59. Jensen EB, Gundersen HJ, Osterby R. Determination of membrane thickness distribution from orthogonal intercepts. J Microsc 1979; 115: 19-33.
60. El-Aouni C, Herbach N, Blattner SM et al. Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrol 2006; 17: 1334-1344.